Zacfit Tablet DEFLAZACORT

Introduction to Zacfit Tablet

Zacfit Tablet is a medication primarily used to manage certain medical conditions by reducing inflammation and suppressing the immune system. It is particularly beneficial for individuals with specific muscle-related disorders.

Composition of Zacfit Tablet

The active ingredient in Zacfit Tablet is Deflazacort, which is a type of corticosteroid. Corticosteroids are a class of drugs that help reduce inflammation and modify the body's immune response.

Uses of Zacfit Tablet

• Treatment of Duchenne muscular dystrophy (DMD) in children aged 5 and older.
• Management of inflammation-related conditions.
• Suppression of the immune system in certain autoimmune diseases.

Side effects of Zacfit Tablet

Common side effects:

• Weight gain
• Increased appetite
• Round face (Cushingoid appearance)
• Upper respiratory infections (common cold)
• Frequent urination
• Nose and throat inflammation
• Excessive hair growth
• Irritability

Serious side effects:

• Allergic reactions such as rash, itching, or swelling
• Severe dizziness
• Trouble breathing

Precautions of Zacfit Tablet

Before taking Zacfit Tablet, inform your doctor if you have any allergies, especially to Deflazacort or any other corticosteroids. Use with caution during pregnancy and breastfeeding. Do not stop taking the medication suddenly, as it may lead to steroid withdrawal syndrome, which includes symptoms like loss of appetite, nausea, vomiting, tiredness, and headache.

How to Take Zacfit Tablet

• Take Zacfit Tablet once daily by mouth.
• The recommended dose is about 0.9 mg for each kilogram of body weight.
• It can be taken with or without food.
• Avoid taking it with grapefruit juice.

Conclusion of Zacfit Tablet

Zacfit Tablet is an effective medication for managing certain inflammatory and muscle-related conditions. It is important to follow your healthcare provider's instructions and be aware of potential side effects. Always consult your doctor for any concerns or questions regarding its use.